DOVATO: Confidence for your patients in a test-and-treat setting
Powerful Efficacy and High Barrier to Resistance at Week 241
Powerful efficacy across baseline viral loads, including those with >1 million copies/mL
Virological Outcomes by Baseline Viral Load or CD4+ T-Cell Count at 24 Weeks (ITT–E Missing=Failure Analysis)1
Adapted from Rolle et al, 20201
*One (<1%) patient had missing plasma HIV-1 RNA results at baseline.1
†Of the 19 patients with baseline viral load ≥500,000 copies/mL, 13 (68%) were suppressed to <50 copies/mL, 4 remained on study with viral load >50 copies/mL (3 <200 copies/mL), and 2 discontinued.1
Confidence in DOVATO for your newly diagnosed patients in a test-and-treat setting
Summary of Virological Outcomes by Week 241
ITT–E Snapshot analysis.
Protecting future treatment options with few modifications
All Participants With Available Data Who Had an ART Adjustment and Remained on a Study at Week 24 Had HIV-1 RNA <50 copies/mL1
A Tolerability Profile You Expect From DTG and 3TC1
- Rolle C-P, Berhe M, Singh T, et al. Feasibility, efficacy, and safety of using dolutegravir/lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV (PLWH): The STAT study. Presented at: 14th annual American Conference for the Treatment of HIV; August 20-22, 2020; Virtual.
- ViiV Healthcare. Rapid test and treat dolutegravir plus lamivudine study in newly diagnosed human immunodeficiency virus (HIV)-1 infected adults. NCT03945981. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03945981 Last accessed February 24, 2021.